- Home
- ACET vs SRTS Comparison
ACET vs SRTS Comparison
Compare ACET & SRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACET
- SRTS
- Stock Information
- Founded
- ACET 1947
- SRTS 2010
- Country
- ACET United States
- SRTS United States
- Employees
- ACET N/A
- SRTS N/A
- Industry
- ACET Biotechnology: Pharmaceutical Preparations
- SRTS Medical/Dental Instruments
- Sector
- ACET Health Care
- SRTS Health Care
- Exchange
- ACET Nasdaq
- SRTS Nasdaq
- Market Cap
- ACET 63.8M
- SRTS 75.5M
- IPO Year
- ACET N/A
- SRTS 2016
- Fundamental
- Price
- ACET $0.62
- SRTS $3.47
- Analyst Decision
- ACET Strong Buy
- SRTS Strong Buy
- Analyst Count
- ACET 7
- SRTS 3
- Target Price
- ACET $5.60
- SRTS $11.67
- AVG Volume (30 Days)
- ACET 371.7K
- SRTS 188.7K
- Earning Date
- ACET 08-07-2025
- SRTS 08-07-2025
- Dividend Yield
- ACET N/A
- SRTS N/A
- EPS Growth
- ACET N/A
- SRTS N/A
- EPS
- ACET N/A
- SRTS N/A
- Revenue
- ACET N/A
- SRTS $37,564,000.00
- Revenue This Year
- ACET N/A
- SRTS $4.33
- Revenue Next Year
- ACET N/A
- SRTS $26.74
- P/E Ratio
- ACET N/A
- SRTS N/A
- Revenue Growth
- ACET N/A
- SRTS 3.29
- 52 Week Low
- ACET $0.45
- SRTS $3.10
- 52 Week High
- ACET $1.64
- SRTS $9.33
- Technical
- Relative Strength Index (RSI)
- ACET 36.75
- SRTS 28.77
- Support Level
- ACET $0.66
- SRTS $5.06
- Resistance Level
- ACET $0.73
- SRTS $5.50
- Average True Range (ATR)
- ACET 0.05
- SRTS 0.40
- MACD
- ACET -0.01
- SRTS -0.10
- Stochastic Oscillator
- ACET 0.00
- SRTS 12.32
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.